Rein Therapeutics Receives Orphan Drug Designation for LTI-03
Rein Therapeutics announced that it has received orphan drug designation from the European Medicines Agency, EMA, for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis, IPF. The designation follows a positive opinion from the EMA's Committee for Orphan Medicinal Products, COMP, and subsequent adoption by the European Commission.
Trade with 70% Backtested Accuracy
Analyst Views on RNTX
About RNTX
About the author
What’s Behind the Rise in Rein Therapeutics Stock on Monday?
Stock Performance: Rein Therapeutics (RNTX) stock rose 16.29% to $1.82, with a trading volume significantly higher than its average.
FDA Approval: The FDA lifted the clinical hold on Rein's Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis, allowing the study to proceed after addressing all concerns.
Trial Details: The trial will resume patient recruitment in late 2025 or early 2026, involving around 20 U.S. sites, and aims to evaluate the safety and efficacy of LTI-03 in up to 120 patients.
Future Expectations: Initial topline data from the trial is anticipated in the third quarter of 2026, complementing a broader global study with additional sites in several countries.
Rein Therapeutics Receives FDA Approval to Continue Phase 2 Trial of LTI-03 for IPF Patients
FDA Lifts Clinical Hold: Rein Therapeutics announced that the FDA has lifted the full clinical hold on its phase 2 trial for LTI-03, allowing the study to proceed after addressing the agency's concerns.
CEO's Statement: Brian Windsor, CEO of Rein Therapeutics, highlighted the FDA's decision as a significant milestone, enabling the company to resume patient enrollment and advance the treatment for idiopathic pulmonary fibrosis (IPF).
Patient Recruitment Timeline: Rein plans to resume patient recruitment in late 2025 or early 2026 at around 20 clinical sites across the U.S., complementing its global RENEW study with additional sites in the UK, Germany, Poland, and Australia.
Trial Objectives: The trial aims to evaluate the safety, tolerability, and efficacy of LTI-03 in up to 120 patients with IPF, focusing on its potential to slow fibrosis and support lung repair.
Rein Therapeutics Granted FDA Approval to Restart Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis in the U.S.
FDA Approval: The FDA has lifted the clinical hold on Rein Therapeutics' Phase 2 trial for LTI-03, allowing the company to resume U.S. patient enrollment expected in late 2025 or early 2026 across 20 clinical sites.
LTI-03 Potential: Early data indicates that LTI-03 may not only slow fibrosis in idiopathic pulmonary fibrosis (IPF) patients but also promote lung healing, representing a dual-action approach to treatment.
Global Study Expansion: The U.S. enrollment will complement a broader global study that includes approximately 30 additional sites in the UK, Germany, Poland, and Australia, aiming to evaluate the safety and efficacy of LTI-03 in up to 120 patients.
Market Need: IPF is a progressive lung disease with limited treatment options, highlighting the urgent need for new therapies, as the global market for fibrosis treatments is projected to exceed $11 billion by 2031.
Rein Therapeutics Granted European Regulatory Clearance to Start Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
EMA Approval for Clinical Trial: Rein Therapeutics has received authorization from the European Medicines Agency (EMA) to initiate its Phase 2 "RENEW" clinical trial for LTI-03, a therapy aimed at treating idiopathic pulmonary fibrosis (IPF), with study sites in Germany and Poland.
Trial Details and Objectives: The RENEW trial will enroll up to 120 patients globally, focusing on the safety, tolerability, and efficacy of LTI-03 over a 24-week treatment period, with key endpoints including lung function changes and fibrosis progression assessments.
HC Wainwright & Co. Begins Coverage of Rein Therapeutics with a Buy Rating and Sets Price Target at $10
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights provided by Benzinga reporters.
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics Presentations: Rein Therapeutics will present at the IPF Summit 2025, with Chief Scientific Officer Cory Hogaboam discussing the role of immune cells in idiopathic pulmonary fibrosis (IPF) and potential treatments, while CEO Brian Windsor will provide insights on their Phase 2 trial of LTI-03 focusing on safety, tolerability, and lung function.
Company Overview: Rein Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for orphan pulmonary and fibrosis conditions, including LTI-03, which targets alveolar epithelial cell survival and profibrotic signaling, and has received Orphan Drug Designation in the U.S.
What’s Behind the Rise in Rein Therapeutics Stock on Monday?
Stock Performance: Rein Therapeutics (RNTX) stock rose 16.29% to $1.82, with a trading volume significantly higher than its average.
FDA Approval: The FDA lifted the clinical hold on Rein's Phase 2 RENEW trial for LTI-03 in idiopathic pulmonary fibrosis, allowing the study to proceed after addressing all concerns.
Trial Details: The trial will resume patient recruitment in late 2025 or early 2026, involving around 20 U.S. sites, and aims to evaluate the safety and efficacy of LTI-03 in up to 120 patients.
Future Expectations: Initial topline data from the trial is anticipated in the third quarter of 2026, complementing a broader global study with additional sites in several countries.
Rein Therapeutics Receives FDA Approval to Continue Phase 2 Trial of LTI-03 for IPF Patients
FDA Lifts Clinical Hold: Rein Therapeutics announced that the FDA has lifted the full clinical hold on its phase 2 trial for LTI-03, allowing the study to proceed after addressing the agency's concerns.
CEO's Statement: Brian Windsor, CEO of Rein Therapeutics, highlighted the FDA's decision as a significant milestone, enabling the company to resume patient enrollment and advance the treatment for idiopathic pulmonary fibrosis (IPF).
Patient Recruitment Timeline: Rein plans to resume patient recruitment in late 2025 or early 2026 at around 20 clinical sites across the U.S., complementing its global RENEW study with additional sites in the UK, Germany, Poland, and Australia.
Trial Objectives: The trial aims to evaluate the safety, tolerability, and efficacy of LTI-03 in up to 120 patients with IPF, focusing on its potential to slow fibrosis and support lung repair.
Rein Therapeutics Granted FDA Approval to Restart Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis in the U.S.
FDA Approval: The FDA has lifted the clinical hold on Rein Therapeutics' Phase 2 trial for LTI-03, allowing the company to resume U.S. patient enrollment expected in late 2025 or early 2026 across 20 clinical sites.
LTI-03 Potential: Early data indicates that LTI-03 may not only slow fibrosis in idiopathic pulmonary fibrosis (IPF) patients but also promote lung healing, representing a dual-action approach to treatment.
Global Study Expansion: The U.S. enrollment will complement a broader global study that includes approximately 30 additional sites in the UK, Germany, Poland, and Australia, aiming to evaluate the safety and efficacy of LTI-03 in up to 120 patients.
Market Need: IPF is a progressive lung disease with limited treatment options, highlighting the urgent need for new therapies, as the global market for fibrosis treatments is projected to exceed $11 billion by 2031.
Rein Therapeutics Granted European Regulatory Clearance to Start Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
EMA Approval for Clinical Trial: Rein Therapeutics has received authorization from the European Medicines Agency (EMA) to initiate its Phase 2 "RENEW" clinical trial for LTI-03, a therapy aimed at treating idiopathic pulmonary fibrosis (IPF), with study sites in Germany and Poland.
Trial Details and Objectives: The RENEW trial will enroll up to 120 patients globally, focusing on the safety, tolerability, and efficacy of LTI-03 over a 24-week treatment period, with key endpoints including lung function changes and fibrosis progression assessments.
HC Wainwright & Co. Begins Coverage of Rein Therapeutics with a Buy Rating and Sets Price Target at $10
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and insights provided by Benzinga reporters.
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025
Rein Therapeutics Presentations: Rein Therapeutics will present at the IPF Summit 2025, with Chief Scientific Officer Cory Hogaboam discussing the role of immune cells in idiopathic pulmonary fibrosis (IPF) and potential treatments, while CEO Brian Windsor will provide insights on their Phase 2 trial of LTI-03 focusing on safety, tolerability, and lung function.
Company Overview: Rein Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for orphan pulmonary and fibrosis conditions, including LTI-03, which targets alveolar epithelial cell survival and profibrotic signaling, and has received Orphan Drug Designation in the U.S.
